WOCKPHARMA Q2 2024 Results: Revenue Up to Rs. 809 Crore, Net Loss Narrows to Rs. 16 Crore from Rs. 73 Crore YoY
NSE:WOCKPHARMA:Rs.1,203.00 (+1.88%)
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Revenue
Revenue for the current quarter (Sep 2024) stands at Rs. 809.00 crore, reflecting an increase of Rs. 70.00 crore compared to Rs. 739.00 crore in the previous quarter (Jun 2024). However, it is slightly higher than the revenue of Rs. 753.00 crore reported in the same quarter last year (Sep 2023).
Net Profit
Net loss for the current quarter (Sep 2024) is Rs. 16.00 crore, which is the same as the loss incurred in the previous quarter (Jun 2024). On the other hand, compared to the net loss of Rs. 73.00 crore in Sep 2023, it shows a significant reduction in the loss.
Profit Margin
The profit margin for the current quarter (Sep 2024) is 14%, an improvement from the 12% profit margin in the previous quarter (Jun 2024). In comparison to the 10% profit margin in Sep 2023, the current quarter’s margin shows notable growth.
EPS
The profit margin for the current quarter (Sep 2024) is 14%, an improvement from the 12% profit margin in the previous quarter (Jun 2024). In comparison to the 10% profit margin in Sep 2023, the current quarter’s margin shows notable growth.
Other Income
Other income for the current quarter (Sep 2024) is Rs. 9.00 crore, which is Rs. 30.00 crore lower than the other income of Rs. 39.00 crore in the previous quarter (Jun 2024). However, it is lower compared to the other income of Rs. 24.00 crore in the same quarter last year (Sep 2023).